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Background Rare variants (minor allele frequency < 1%
or 5 %) can help researchers to deal with the confounding
issue of ‘missing heritability’ and have a proven role in
dissecting the etiology for human diseases and complex
traits.
Methods We extended the combined multivariate
and collapsing (CMC) and weighted sum statistic (WSS)
methods and accounted for the effects of population
stratification and subgroup effects using stratified
analyses by the principal component analysis, named here
as ‘str-CMC’ and ‘str-WSS’. To evaluate the validity of the
extended methods, we analyzed the Genetic Architecture
of Smoking and Smoking Cessation database, which
includes African Americans and European Americans
genotyped on Illumina Human Omni2.5, and we compared
the results with those obtained with the sequence kernel
association test (SKAT) and its modification, SKAT-O that
included population stratification and subgroup effect
as covariates. We utilized the Cochran–Mantel–Haenszel
test to check for possible differences in single nucleotide
polymorphism allele frequency between subgroups
within a gene. We aimed to detect rare variants and
considered population stratification and subgroup

effects in the genomic region containing 39 acetylcholine
receptor-related genes.
Results The Cochran–Mantel–Haenszel test as
applied to GABRG2 (P = 0.001) was significant. However,
GABRG2 was detected both by str-CMC (P = 8.04E-06)
and str-WSS (P = 0.046) in African Americans but not by
SKAT or SKAT-O.
Conclusions Our results imply that if associated
rare variants are only specific to a subgroup, a stratified
analysis might be a better approach than a combined
analysis. Psychiatr Genet 29:111–119 Copyright © 2019
The Author(s). Published by Wolters Kluwer Health, Inc.
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Background

Cigarette smoking is a primary risk factor for many chronic
diseases (Bergen and Caporaso, 1999) including many
cancers, diabetes, cardiovascular disease, and chronic lung
disease (Fang et al.`, 2014). Recent candidate-gene association studies (Fang et al., 2014) and genome-wide association studies (GWASs) (Thorgeirsson et al., 2010), many
of which have been reviewed by Wang and Li (2010),
have searched for and, at varying levels of significance,
identified common variants associated with measures
of response to tobacco, tobacco consumption, nicotine
dependence, nicotine metabolism, and smoking cessation.
Supplemental Digital Content is available for this article. Direct URL citations
appear in the printed text and are provided in the HTML and PDF versions of this
article on the journal’s website, www.psychgenetics.com.
This is an open-access article distributed under the terms of
Commons Attribution-Non Commercial-No Derivatives License
NC-ND), where it is permissible to download and share the work
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Current smoking prevalence is similar in European
Americans and African Americans (Centers for Disease
and Prevention, 2008; Saccone et al., 2010; Choi et al.,
2017). Nicotine dependence is common in both groups,
with evidence of slightly lower levels of dependence in
African Americans by standard measures such as cigarettes per day currently in use (Breslau et al., 2001; Saccone
et al., 2010). Smoking cessation rates, however, are lower
in African Americans compared with European Americans
(Breslau et al., 2001; Covey et al., 2008; Saccone et al., 2010;
Choi et al., 2017). Furthermore, there is evidence that
African Americans have a higher risk of dependence at
lower cigarettes-per-day levels compared with European
Americans (Luo et al., 2008; Saccone et al., 2010). Also
important are the disparities in health consequences from
smoking: African Americans have higher lung cancer incidence and mortality than European Americans (Haiman
et al., 2006; Jemal et al., 2008; Saccone et al., 2010). An
understanding of the genetic loci involved, and their
effects and allele frequencies in diverse populations, can
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provide important clues to the risk of developing nicotine
dependence across all populations. Multiple nicotinic
receptor subunit genes outside of chromosome 15q25
are likely to be important in the biological processes and
development of nicotine dependence, and some of these
risks may be shared across diverse populations (Saccone
et al., 2010).
GWASs constitute an important means for identifying
risk genes for complex human diseases, such as diabetes
(Hindorff et al., 2009; Dajani et al., 2017), heart disease
(Hofker et al., 2014; Erdmann et al., 2018), and Alzheimer’s
disease (Shen and Jia, 2016; Chung et al., 2018), among
others. Despite many successes in identifying risk alleles,
most associated variants discovered through GWAS do not
account for the majority of heritability estimated for these
complex human diseases and traits. From a genetics perspective, by far the most studied of these complex human
diseases and traits can be attributed to heritability about
an estimated 60–80% of human disease (Lichtenstein
et al., 2009), whereas GWAS have identified only 5–10%
of this heritability, leading many researchers to ponder
which alleles underlie the missing heritability (Manolio
et al., 2009; Zuk et al., 2014; Auer and Lettre, 2015). One
of the approaches to deal with missing heritability is to
detect new DNA variants, especially rare variants that
have a relatively large impact on disease etiology, that is,
those with minor allele frequency <5%, which may also
contribute to complex disease (Schork et al., 2009; Marian,
2012; Gusev et al., 2013; Zuk et al., 2014; Auer and Lettre,
2015; Ma et al., 2015; Nicolae, 2016). With efforts from the
1000 Genomes Project, which sought to identify most rare
genetic variants in a group of 1092 multiethnic individuals, a new generation of GWAS is being designed to enable the discovery of rare variants using next-generation
sequencing data (Abecasis et al., 2012; Sampson
et al., 2012). Hence, improved technologies for discovering rare variants provide a possible means of explaining
the missing heritability.
A number of methods have been developed for identifying associations between rare variants and common
diseases (Li and Leal, 2008; Madsen and Browning,
2009; Schork et al., 2009). Madsen and Browning (2009)
proposed a weighted sum statistic (WSS) method that
assigns weights to variants according to their frequency
in controls such that the variants with lower frequencies
have greater weights. Li and Leal (2008) proposed the
combined multivariate and collapsing (CMC) method for
case-control data. Wu et al. (2011) proposed a sequence kernel association test (SKAT), that is, a variance-component
method that aggregates individual variant-score test statistics. However, population structure and subgroups
can be strong confounding factors in association studies
(Pritchard et al., 2000; Ziv and Burchard, 2003; Clayton
et al., 2005; Roeder and Luca, 2009), and thus accounting for population structure and subgroups is crucial
even when seemingly homogeneous ethnic populations

are sampled. To our knowledge, only a few articles have
discussed rare-variant detection and considered population stratification and subgroup effects [e.g., reviewed by
Moore et al. (2013), O’Connor et al. (2013), Wang et al.
(2015), Prokopenko et al. (2016)] for nicotine dependence and smoking cessation studies (Saccone et al., 2010).
However, whether population stratification would be better than dealt with using stratified analyses or including
population simply as a covariate has not been studied
enough (Culverhouse et al., 2011).
To achieve this goal, we evaluated the issue by considering
two situations: (1) assessing the strata in separate analyses
and (2) pooling data from all strata, using population as a
covariate. The results from the two situations were then
compared. We utilized the Cochran–Mantel–Haenszel
(CMH) test to check whether the allelic distribution of single nucleotide polymorphisms (SNPs) is similar between
the population stratifications/subgroups. Furthermore, we
extended WSS and CMC to identify rare variants while
also considering population stratification and subgroup
effects using stratified analyses by principal component
analysis (PCA), named here as ‘str-CMC’ and ‘str-WSS’.
To compare results obtained with the two aforementioned
situations for nicotine dependence and smoking cessation studies, we analyzed a smoking cessation dataset to
test for rare variants associated with nicotine dependence
which was downloaded from the Database of Genotypes
and Phenotypes (accession number phs000404.v1.p1).
The smoking cessation dataset was from the Collaborative
Genetic Study of Nicotine Dependence (COGEND;
principal investigator: Laura Bierut) and the University of
Wisconsin Transdisciplinary Tobacco Use Research Center
(UW-TTURC; principal investigator: Timothy Baker).
Evidence has recently accumulated that SNPs in the
genetic region encoding the nicotinic acetylcholine receptor (nAChR) subunits α6, α5, α3, and β4 are associated with
smoking and nicotine dependence (Russo et al., 2011). For
the smoking cessation dataset analyses, we were only interested in the acetylcholine receptor region that has been
reported previously.
To evaluate the issue by considering two situations,
we compared the results to those obtained with two
variance-component methods, namely, SKAT (Wu et al.,
2011) and optimal sequencing kernel association test
(SKAT-O) (Lee et al., 2012), which treat both population
stratification and subgroup effects in the PCA as covariates. In our results, we found ethnicity (i.e., African
American and European American) was associated
with the first axis of variation (PC1) arising from PCA
(Supplementary Additional file 2, Supplemental digital content 2, http://links.lww.com/PG/A221). Our results
imply that if a gene showed allele frequency differences
between the two groups, it would be better to use strCMC or str-WSS in detecting associated rare variants.
By contrast, if a gene has a similar distribution of allele
frequency between the two groups, this would be better

Copyright © 2019 Wolters Kluwer Health, Inc. Unauthorized reproduction of this article is prohibited.

Association studies of rare genetic variants Hsieh et al.

dealt with by including population stratification and subgroup effects as covariates in SKAT or SKAT-O. These
results will assist researchers in identifying a biological
basis for the etiology of nicotine dependence.

Materials and methods

The CMC and WSS cannot be adjusted for covariates.
However, the SKAT and SKAT-O are able to adjust for
covariates (Liang and Xiong, 2013). We evaluated rare variant methods for dealing with population subgroups: (1)
CMC and WSS were analyzed population subgroups in
population stratification analyses, that is, str-MSS and strWSS and (2) SKAT and SKAT-O were combined data from
all population subgroups, using population subgroups as
a covariate. First, we calculated the first axis of variation
(PC1) using the EIGENSTRAT software (Price et al.,
2006) to consider population stratification and subgroup
effects. PCA is a linear dimensionality reduction technique used to infer continuous axes of genetic variation.
Price et al. (2006) developed the program EIGENSTRAT
to correct for population structure in association tests.
It uses the top eigenvectors of the sample covariance
matrix as covariates in a regression setting. Second, we
performed the CMH test (Mantel and Haenszel, 1959)
to assess differences in SNP allele frequencies between
subgroups by the results of the PC1 arising from PCA.
The CMH test was two-tailed for all analyses. To investigate the homogeneity association assumption, we used
the Breslow–Day test and found no significant evidence
for heterogeneity association. Third, we detected rare variants and accounted for the effects of population stratification and subgroup effects. Rare genetic variants, here
defined as alleles with a frequency less than 1–5% (Wu
et al., 2011). For all rare variant methods, rare variants
were detected within a gene, a minor allele frequency of
less than 5% was used as the rare-variant criterion.
Smoking cessation data

Our analyses were based on a publicly available smoking cessation dataset from the Database of Genotypes
and Phenotypes (http://www.ncbi.nlm.nih.gov/sites/
entrez?db=gap) (accession number phs000404.v1.p1).
Genotyping during the GWAS discovery phase used the
HumanOmni2.5 BeadChip designed to analyze 2 443 179
loci. All individuals (n = 1515) in the study were from two
projects: COGEND (principal investigator: Laura Bierut)
and UW-TTURC (principal investigator: Timothy
Baker). The individuals reported smoking at least 10
cigarettes per day. Both International Classification of
Diseases 10th Revision (ICD-10) (Janca et al., 1993) and
Diagnostic and Statistical Manual of Mental Disorders
(DSM-IV) have separate categories for dependent and
nondependent smokers. The ICD-10 and the DSM-IV
are unsatisfactory and are rarely used for daily clinical
care because they cannot be tailored treatments to individual needs (Helzer et al., 2006; Rüther et al., 2014).
However, the Fagerström Test for Nicotine Dependence
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(FTND) measures tobacco dependencies as dimension
parameters and uses continuums to indicate the severity of the dependency. Thus, the FTND has become
an internationally recognized and proven method for
determining tobacco dependence (Heatherton et al.,
1991; Rüther et al., 2014). For this reason, we binned
cases and controls based on the FTND when evaluating
smoking cessation.
Both COGEND and UW-TTURC projects assessed nicotine dependence using the FTND (Heatherton et al.,
1991). The FTND is a six-item self-report measure of
nicotine dependence. FTND scores on the scale range
from 0 to 10 and also categorized accordingly: 2 = very
low dependence; 3–4 = low dependence; 5 = moderate
dependence; 6–7 = high dependence; and 8+ = very high
dependence (López-Torrecillas et al., 2017). For the current study, cases were defined as having a nicotine dependence if the score for this test was at least 6; all controls had
a score of or less 4. To avoid potential rare variant detection biases associated with misclassification of FTND
scores due to FTND breakpoints (López-Torrecillas
et al., 2017), our study ignored participants with an FTND
score of 5 and analyzed two groups of participants with
large differences in FTND score. According to this definition, there were 923 cases (135 African Americans and
788 European Americans) and 592 controls (69 African
Americans and 523 European Americans).
For this dataset, we were only interested in the acetylcholine receptor region that has been reported previously
as being candidate genes of smoking cessation (Conti
et al., 2008). According to Conti et al. (2008), several studies have identified associations of genetic regions encoding the nAChRs with nicotine dependence (Saccone
et al., 2007) and with smoking cessation (Berrettini
et al., 2007). Therefore, the nAChRs list was analyzed
by Ingenuity Pathways Analysis was performed (IPA;
Ingenuity H Systems, Redwood City, CA, USA; (http://
www.ingenuity.com) to explore the possibility of identifying gene candidates previously reported in the literature findings from Ingenuity Knowledge Base. All possibility
of identifying gene candidates searched from IPA were
listed in Supplementary Additional file 1, Supplemental
digital content 1, http://links.lww.com/PG/A220.
Combined multivariate and collapsing with population
stratification and subgroup effects (str-CMC)

CMC (Li and Leal, 2008) aggregates multiple rare variants
across a genomic region (e.g., gene, haplotype, and pathway) and analyzes them together. CMC divides markers
into subgroups based on predefined criteria (e.g., allele
frequency) and, within each group, marker data are collapsed into an indicator variable. The procedure we used
consisted of the following four steps: (1) data were divided
into subgroups by the first axis of variation (PC1) using
EIGENSTRAT software (Price et al., 2006); (2) markers
in each gene group were classified as either rare variants
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or common variants; (3) markers in each gene group are
divided into subgroups on the basis of predefined criteria
(e.g., allele frequencies), and within each group, marker
data are collapsed into indicator variables defined for the
genotype at the ith variant site for the jth individual in
the case population ( X ji ) and control population ( Y ji ),
1 Genotype is AA
1 Genotype is AA

0 Genotype is Aa ,Y = 0 Genotype is Aa
X
=
respectively: ji 
ji

-1 Genotype is aa
-1 Genotyppe is aa


as described in Li et al., 2008 (Li and Leal, 2008); and (4)
Hotelling’s T2 test was used to compare the groups of
marker data in each k-gene group. This procedure was
named as ‘str-CMC’.
Weighted sum statistic with population stratification
and subgroup effects (str-WSS)

Madsen and Browning (2009) described WSS, which
determines a weighted rare-variant count in a genomic
region (e.g., gene, haplotype, and pathway). The weights
are determined according to the variance of the allele
frequency estimated for cases and controls, with downweight mutation counts in constructing the genetic score
as bellow. The procedure we use consisted of the following five steps: (1) data were divided into subgroups
by the PC1 using EIGENSTRAT software (Harvard
University, USA; https://www.hsph.harvard.edu/alkesprice/software/) (Price et al., 2006); (2) a set of markers
were divided into k genomic regions; (3) the genetic
score as described in Madsen and Browning (2009) was
calculated for each gene. Madsen and Browning (2009)
L

I

defined the genetic score as follows: S j = ∑ ij
i =1

wi

where I ij is the number of mutations (usually this will
be the minor allele, unless common allele was reported
susceptibility to disease) in variant i for individual j in a
genomic region, L is the number of variants genotyped,

and i = 1, 2,…, L. The weight, wi = ni ⋅ qi (1 − qi ) , is the
estimated SD of the total number of mutations in the
sample (including cases and controls), under the null
hypothesis of no frequency differences between cases
miU + 1
, miU is the number of
2niU + 2
mutant alleles observed for variant i in the controls, niU
is the number of controls genotyped for variant i, and ni

and controls, where qi =

is the total number of individuals genotyped for variant
i (cases and controls); (4) genetic scores were ranked for
the cases and controls combined; and (5) a Wilcoxon rank
sum test was used to test for association between the set
of rare variants and disease status via permutation tests.
This procedure was named ‘str-WSS’.
Sequence kernel association test-based methods

SKAT (Wu et al., 2011) and SKAT-O (Lee et al., 2012) use
a multiple regression model to directly correlate a phenotype with genetic variants in a genomic region (e.g., gene,
haplotype, and pathway) and with covariates by the PC1
using EIGENSTRAT software (Price et al., 2006).

Results

A total of 2 295 169 SNPs in chromosomes 1–22 were
excluded according to the following quality-control criteria: genotype call rate < 0.95, or departure from Hardy–
Weinberg equilibrium (P < 10–4) for the control group.
Missing SNPs were imputed using Beagle: Univer
sity of Washington, USA; https://faculty.washington.
edu/browning/beagle/beagle.html. Beagle produces a
measure r2 to estimate the squared correlation between
imputed and true alleles for the marker. For quality control (QC) purpose, we excluded SNPs with r2 less than
0.3. Finally, we used 1785 SNPs in acetylcholine receptor
region that has been reported previously as being candidate genes of smoking cessation (Conti et al., 2008)
str-CMC

After using EIGENSTRAT software (Price et al., 2006),
we found that ethnicity was the first axis of variation
(PC1) arising from PCA. Hence, we divided the data into
two subgroups, that is, groups European Americans and
African Americans.
The acetylcholine receptor genes CHRNA5 (cholinergic receptor, nicotinic, alpha 5) (P = 0.038) and PSMA4
(proteasome subunit alpha 4) (P = 0.019) of group
European Americans were identified by str-CMC (Fig. 1;
Supplementary Additional file 1, Supplemental digital
content 1, http://links.lww.com/PG/A221). CHRNA5 is associated with risk of failure for individuals who attempt to
reduce cigarette smoking (Chen et al., 2014) and contributes to lung cancer susceptibility in smoking-associated
nasopharyngeal carcinoma (Ji et al., 2014). PSMA4 is associated with lung cancer risk in Caucasians and African
Americans (Hansen et al., 2010).
The following genes of group African Americans were
identified by str-CMC (Fig. 1; Supplementary Additional
file 1, Supplemental digital content 1, http://links.lww.
com/PG/A221): GABRB2 (gamma-aminobutyric acid A
receptor, beta 2) (P = 2.20E-05), GABRG2 (gamma-aminobutyric acid A receptor, gamma 2) (P = 8.04E-06),
JAK2 (Janus kinase 2) (p=6.58E-07), DRD2 (dopamine
receptor D2) (P = 2.92E-04), RAPSN (receptor-associated protein of the synapse) (P = 0.031), RIC3 (RIC3
acetylcholine receptor chaperone) (P = 0.005), CHRM5
(cholinergic receptor, muscarinic 5) (P = 0.03), CHRNA7
(cholinergic receptor, nicotinic, alpha 7) (P = 5.49E06), CHRNE (cholinergic receptor, nicotinic, epsilon)
(P = 0.0176), CDH2 (cadherin 2, type 1, N-cadherin)
P < 0.00000001), and APP [amyloid beta (A4) precursor protein] (P < 0.00000001). GABRB2 is associated
with susceptibility to drug addiction (Hondebrink et al.,
2013), psychiatric disorders (Zhao et al., 2012), and nonsmall cell lung cancer (Zhang et al., 2013). GABRG2 is
also associated with epilepsy (Reinthaler et al., 2015) and
may contribute to the potential for suicidal behavior in
schizophrenia patients with alcohol dependence or abuse
(Zai et al., 2014). PTK2B is associated with nonsmall
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Fig. 1

(a) The Venn diagram of rare variants detected by str-CMC in European Americans (str-CMC_European Americans), African Americans (str-CMC_
African Americans) and CMC. A color scheme of gene symbol is used to display CMH results with blue for significance, black for no significance.
(b) The Venn diagram of rare variants detected by str-WSS in European Americans (str-CMC_European Americans), African Americans
(str-WSS_African Americans) and WSS. (c) The Venn diagram of rare variants detected by SKAT and SKAT-O. CMC, combined multivariate and
collapsing; WSS, weighted sum statistic.

cell lung cancer (Kuang et al., 2013). Mutations in JAK2,
when considered in the context of cigarette smoking status, can affect breast cancer–specific mortality (Slattery
et al., 2014). Although Choi et al. (2015) did not find a
significant relationship between DRD2 polymorphisms
and success during smoking cessation therapy, DRD2 was
found to be associated with nicotine and alcohol addiction
(Ma et al., 2015). RIC3 is associated with nicotinic receptor assembly, expression, and nicotine-induced receptor
upregulation (Dau et al., 2013). CHRM5 may be involved
in addiction to tobacco and cannabis, but not alcohol, in
group European Americans (Anney et al., 2007). CHRNA7
may be involved in the development of physical dependence on nicotine (Kishioka et al., 2014).
str-WSS

The following genes of group European Americans were
found by str-WSS (Fig. 1; Supplementary Additional file
1, Supplemental digital content 1, http://links.lww.com/PG/
A221): CHRNA2 (P = 0.038), JAK2 (P = 0.013), CHRNA3
(P = 0.011), CHRNA5 (P = 0.002), and PSMA4 (P = 0.004).

CHRNA2 is associated with nicotine dependence in
groups European Americans and African Americans
(Wang et al., 2014) and with smoking cessation (Heitjan
et al., 2008). CHRNA3 is associated with nicotine dependence (Munafò et al., 2011), and CHRNA3 polymorphisms
are genetic modifiers of the risk for developing lung adenocarcinoma (He et al., 2014). However, CHRNA3 may
not merely operate as a marker for the difficulty, willingness, or motivation to quit smoking (Munafò et al., 2011).
The following genes were identified by str-WSS in group
African Americans (Fig. 1; Supplementary Additional
file 1, Supplemental digital content 1, http://links.lww.
com/PG/A221): GABRG2 (P = 0.046), RAPSN (P = 0.011),
CHRNA5 (P = 0.039), CHRNA7 (P = 0.016), and CHRNB1
(P = 0.046), whereas CHRNB1 is associated with the
African Americans sample, no significant association was
found in group European Americans (Lou et al., 2006).
Sequence kernel association test and SKAT-O

We also observed an African American to European
American difference that was the result of the first axis of
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variation (PC1) arising from PCA using EIGENSTRAT
software (Price et al., 2006). Hence, we used a subgroup
effect as a covariate in SKAT and SKAT-O.
The following genes were detected by SKAT: CHRNA1
(P = 0.001, Fig. 1; Supplementary Additional file 1,
Supplemental digital content 1, http://links.lww.com/
PG/A221), UBQLN1 (P = 0.025, Fig. 1; Supplementary
Additional file 1, Supplemental digital content 1, http://
links.lww.com/PG/A221), and CHRM1 (P = 0.041, Fig. 1;
Supplementary Additional file 1, Supplemental digital
content 1, http://links.lww.com/PG/A221). CHRNA1 is associated with smoking cessation (Rose et al., 2010) and lung
adenocarcinoma (Chang et al., 2013). UBQLN1 is associated with smoking cessation (Rose et al., 2010) and nonsmall cell lung cancer (Shah et al., 2015).
The following genes were detected by SKAT-O: CHRNA1
(P = 0.015), CHRND (P = 0.034), UBQLN1 (P = 0.034),
CHRM1 (P = 0.013), CHRNA3 (P = 0.018), and CHRNA5
(P = 0.048). CHRND has been reported to be related to
modify the risk for nicotine dependence associated with
peer smoking (Johnson et al., 2010).
Comparison of the rare variant–associated results from
str-CMC, str-WSS, sequence kernel association test,
and SKAT-O

We applied CMH analysis to the 39 acetylcholine receptor-related genes, which revealed that 15 of these genes
had differences in SNP allele frequencies between
subgroups after controlling for different groups arising
from PCA using EIGENSTRAT software (Price et al.,
2006) (i.e., European Americans and African Americans)
(Fig. 1; Supplementary Additional file 1, Supplemental
digital content 1, http://links.lww.com/PG/A221). Among
these 15 genes (with different SNP allele frequencies),
str-CMC found 10 genes (two in European Americans
and eight in African Americans) and str-WSS detected
six genes (four in European Americans, one in African
Americans; one in both European Americans and African
Americans). However, SKAT and SKAT-O detected
only 1 genes (Fig. 1; Supplementary Additional file 1,
Supplemental digital content 1, http://links.lww.com/PG/
A221). By contrast, we found 22 genes that did not differ with respect to SNP allele frequency between subgroups after controlling for different groups arising from
PCA using EIGENSTRAT software. Of these 22 genes,
str-CMC detected three genes (0 in European Americans
and three in African Americans) and str-WSS detected
two genes (0 in European Americans and two in African
Americans). SKAT and SKAT-O also detected five genes
(Fig. 1; Supplementary Additional file 1, Supplemental
digital content 1, http://links.lww.com/PG/A221).
For investigating differences between population stratification and combined analyses (a within test comparison),
among these 15 genes (with different SNP allele frequencies) in population stratification analyses, str-CMC

found 10 genes (two in European Americans and eight
in African Americans). By contrast, in combined analyses, CMC only found two of them. However, str-WSS
(detected six genes) and WSS (detected five genes) had
comparable performance in these 15 genes.
The results indicated that for this dataset, two subgroups,
that is, group European Americans and African Americans
as a covariate was not an effective substitute for analyzing
subgroups separately when only one of them contained
an associated rare variant.

Discussion

We determined whether population stratification and
subgroup effects would be better dealt with using stratified analyses or including population as a covariate. Upon
comparing results from str-CMC, str-WSS, SKAT, and
SKAT-O, we found that the inclusion of samples from
other subgroups often introduced noise when the signal
for a particular gene was strong in one of the subgroups.
Without stratification analysis using CMC, in the CMH
test, for example, the result for GABRG2 was significant
at P = 0.0009. However, with stratification analysis using
str-CMC, the P value for GABRG2 was P = 0.00000804
(Fig. 1; Supplementary Additional file 1, Supplemental
digital content 1, http://links.lww.com/PG/A221) and it
was P = 0.046 for str-WSS in African Americans. On the
other hand, GABRG2 was not significant by using SKAT
(P = 0.40426) and SKAT-O (P = 0.60138). In addition,
GABRG2, GABRB2, CHRNA2, JAK2, RIC3, AGPHD1,
PSMA4, CHRNA5, CHRNA3, CHRNB4, CHRM5,
CHRNE, CDH2, and APP were significant in subsamples
representing more than half of the data, and dealing with
the strata in separate analyses increased the chances for
detecting associated rare variants.
Despite the allele frequencies not being different according to CMH test, CHRNA1 was not significant using
CMC and WSS. However, by using SKAT and SKAT-O,
the P value is borderline significant (P = 0.01, Fig. 1;
Supplementary Additional file 1, Supplemental digital
content 1, http://links.lww.com/PG/A221).
By using these data, our results demonstrated that all
rare-variant association methods considered here could
yield a relatively high rate of spurious associations in the
presence of fine-scale population structure. In addition,
we showed that considering for the effects of population
stratification and subgroup effects can confound rare variant analyses. The differences in disease risk between
subgroups that generated such high spurious association
rates are plausible and it is important for further interpreting rare-variant association results. For instance, there is
a 2.5–10% difference in the prevalence of lung cancer
among different populations of European men, although
there is a less striking difference for women (Boyle and
Ferlay, 2005). In our study, GABRG2 was detected by strCMC (P = 8.04E-06, Fig. 1; Supplementary Additional
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file 1, Supplemental digital content 1, http://links.lww.com/
PG/A221) and str-WSS (P = 0.046, Fig. 1; Supplementary
Additional file 1, Supplemental digital content 1,
http://links.lww.com/PG/A221) in African Americans. By
using SKAT and SKAT-O, the P values for GABRG2
are 0.404 and 0.601, respectively (Supplementary
Additional file 1, Supplemental digital content 1,
http://links.lww.com/PG/A220). GABRG2 was not detected
by the two tests if stratification was not considered.
GABRG2 was also associated with addiction (Klee
et al., 2012) and alcohol use disorder (Li et al., 2014; Zai
et al., 2014). In our study, GABRG2 might affect nicotine
dependence risk in African Americans.
Gene-based methods for detecting rare variants are as
effective as the SNP-based methods for GWAS (Schaid
et al., 2005; Wessel and Schork, 2006; Tzeng and Zhang,
2007). The grouping of multiple SNPs within a genomic
region allows combined calculations to enhance statistical power, because rare variants include extremely sparse
data so that traditional SNP-set methods for common variants might not be applicable to rare-variant detection.
Some well-known rare-variant detection methods can
potentially be used to combine low-frequency SNPs in
GWAS. However, the number of SNPs in a gene might
be important in the rare variant detection methods. For
genes with larger numbers of markers, such as acetylcholine receptor-related genes, CMC and str-CMC were
more likely to detect the effects compared with other
methods, that is, WSS, str-WSS, SKAT, and SKAT-O. For
example, in our study, we identified 262 SNPs in APP
and 180 in CDH2 by str-CMC in group African Americans
(Supplementary Additional file 1, Supplemental digital
content 1, http://links.lww.com/PG/A220).
Population structure and subgroups can be strong confounding factors in association studies (Pritchard et al.,
2000; Ziv and Burchard 2003; Clayton et al., 2005; Roeder
and Luca, 2009), so their effects need to be taken into
account. To tackle this problem, we used EIGENSTRAT
software (Price et al., 2006) that can remove some of their
effects. However, the number of principal components
used should depend on the distribution of the eigenvalues (Jiang and Dong, 2011) and sample sizes of subgroups.
Rare variant-detection methods can divide into two main
categories: burden and variance-component tests (Bansal
et al., 2010) such that they should complement each other
for the purpose of identifying possible risk factors for
nicotine dependence or other complex traits. Nicotine
usage is associated with 5 million deaths per year worldwide and is considered one of the gateway drugs that lead
to the use of illicit drugs. Before detecting rare variants,
the CMH test can be used to determine whether there
are any possible differences in SNP allele frequencies
between subgroups within a gene/genomic region/haplotype/pathway. If in a gene differences in SNP allele frequencies between subgroups occur, stratification analyses
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such as str-CMC or str-WSS should be used in detecting
rare variants. Hence, CMH should first be used in rare
variant detection analysis. By contrast, when SNP allele
frequencies between subgroups are similar all methods
can be used directly.
In our study, we cannot fully determine whether the
results demonstrate the differences between population
stratification versus combined analyses, or whether they
reflect the differences between the statistical approaches.
Because the population stratification/combined analyses
and statistical approaches are fundamentally different,
these methods should be considered complementary to
each other when studying rare variants in various disease
analyses. In our study, the small sample size for the African
Americans population is a limitation, particularly when
addressing a question involving low-frequency variants. It
is difficult to interpret how much of the results are driven
by the small numbers in the African Americans group. In
future studies, we will adopt a pairwise sampling design
based on Imai et al. (2015) to increase sample sizes.
In conclusion, we have extended the CMC and WSS
methods to identify rare variants and stratify by population/subgroups while analyzing smoking cessation data.
We found that including population as a covariate was
not an effective substitute for analyzing the subpopulations separately when only one subpopulation contained
a rare variant linked to the phenotype. The conclusion is
the same as previous study findings (Culverhouse et al.,
2011). Our results will help researchers overcome population stratification and subgroup effects when detecting
rare variants. More importantly, these analyses showed
that even when an identical genetic model is applied to
multiple subgroups, sample size is not the only factor that
determines association results. If rare causative variants are
unique to a subgroup, stratified analyses might be more
powerful than combined analyses although stratified analyses may entail a considerable decrease in the sample size.
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